دورية أكاديمية

The cannabinoid R(+)methanandamide induces IL-6 secretion by prostate cancer PC3 cells.

التفاصيل البيبلوغرافية
العنوان: The cannabinoid R(+)methanandamide induces IL-6 secretion by prostate cancer PC3 cells.
المؤلفون: Olea-Herrero, Nuria, Vara, Diana, Malagarie-Cazenave, Sophie, Díaz-Laviada, Inés
المصدر: Journal of Immunotoxicology; Oct2009, Vol. 6 Issue 4, p249-256, 8p, 6 Graphs
مصطلحات موضوعية: PROSTATE cancer, CANNABINOIDS, CYTOKINES, INTERLEUKIN-6, CELL proliferation, IMMUNE system
مستخلص: In the present study, we have investigated the effect of the cannabinoid R(+)methanandamide (MET) in the androgen-resistant prostate cancer PC3 cells. MET induced a dose-dependent decrease in PC3 cell viability as well as a dose-dependent increase in the secretion of the cytokine IL-6. Looking deeper into the mechanisms involved, we found that MET-induced de novo synthesis of the lipid mediator ceramide that was blocked by the ceramide synthase inhibitor Fumonisin B1. Pre-incubation of cells with the cannabinoid receptor CB2 antagonist SR 144528 (SR2), but not the CB1 antagonist Rimonabant or the TRPV1 antagonist capsazepine, partially prevented the anti-proliferative effect, the ceramide accumulation, and the IL-6-induced secretion, suggesting a CB2 receptor-dependent mechanism. Fumonisin B1 did not have any effect in the IL-6 secretion increase induced by MET. However, even an incomplete down-regulation of (i.e., not a total silencing of) ceramide kinase expression by specific siRNA prevented the MET-induced IL-6 secretion. These results suggest that MET regulates ceramide metabolism in prostate PC3 cells which is involved in cell death as well as in IL-6 secretion. Our findings also suggest that CB2 agonists may offer a novel approach in the treatment of prostate cancer by decreasing cancer epithelial cell proliferation. However, the interaction of prostate cancer cells with their surrounding, and in particular with the immune system in vivo, needs to be further explored. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Immunotoxicology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:1547691X
DOI:10.3109/15476910903241696